Skip to main content
. 2022 Sep 8;84:104253. doi: 10.1016/j.ebiom.2022.104253

Figure 1.

Figure 1

HIV-specific CD8+ T cell numbers before ART initiation in AHI and CHI and under long-term ART. (a) Sequence logo for the 5 HIV CD8+ T cell epitopes tested with tetramers: GK10, QK10, AK9, YI9, CL9. The sequence conservation for each epitope was measured using reference datasets of circulating CRF01_AE sequences. The relative size of each AA letter at a site represents the frequency of the residue across circulating viruses. The total height indicates the information content of the position. (b) Number of HIV- and EBV-specific tetramer+ CD8+ T cells per mL of peripheral blood in individuals prior to ART initiation in AHI (UnTx AHI, n=19) or CHI (UnTx CHI, n=15). (c) Number of HIV-specific CD8+ T cells before (UnTx) and during (Tx) long-term ART measured longitudinally in individuals who initiated treatment in AHI or CHI and were on ART for more than 1 year. (d) Number of HIV- and EBV-specific tetramer+ CD8+ T cells in individuals who initiated treatment in AHI (n=41) or in CHI (n=27) and were on ART for more than 1 year. Differences between UnTx AHI group, UnTx CHI group, and EBV-specific CD8+ T cells were analyzed by a Kruskal-Wallis test. Differences between samples collected before and after ART were analyzed by a Wilcoxon test. *P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001.